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Abstract
Mitochondria are the primary intracellular site of oxygen consumption and the major source of reactive oxygen
species (ROS), most of them originating from the mitochondrial respiratory chain. Among the arsenal of anti-
oxidants and detoxifying enzymes existing in mitochondria, mitochondrial glutathione (mGSH) emerges as the
main line of defense for the maintenance of the appropriate mitochondrial redox environment to avoid or repair
oxidative modiﬁcations leading to mitochondrial dysfunction and cell death. mGSH importance is based not
only on its abundance, but also on its versatility to counteract hydrogen peroxide, lipid hydroperoxides, or
xenobiotics, mainly as a cofactor of enzymes such as glutathione peroxidase or glutathione-S-transferase (GST).
Many death-inducing stimuli interact with mitochondria, causing oxidative stress; in addition, numerous pa-
thologies are characterized by a consistent decrease in mGSH levels, which may sensitize to additional insults.
From the evaluation of mGSH inﬂuence on different pathologic settings such as hypoxia, ischemia=reperfusion
injury, aging, liver diseases, and neurologic disorders, it is becoming evident that it has an important role in the
pathophysiology and biomedical strategies aimed to boost mGSH levels. Antioxid. Redox Signal. 11, 2685–2700.
Introduction
The tripeptide glutathione (g-l-glutamyl-l-cysteinyl-glycine, GSH), the main nonprotein thiol found in cells, is
synthesized in the cytosol in two steps that require ATP. First
is the formation of g-glutamylcysteine from glutamate and
cysteine, by the activity of the g-glutamylcysteine synthetase,
followed by the formation of GSH by the activity of GSH
synthetase, which uses g-glutamylcysteine and glycine as
substrates (Fig. 1). The formation of g-glutamylcysteine is the
rate-limiting reaction in GSH synthesis and is feedback in-
hibited by GSH itself, a mechanism responsible for the regu-
lation of cellular GSH concentration. Virtually all mammalian
cells have the capacity to synthesize GSH. Because of the
presence of cysteine in its backbone, GSH is essential in the
regulation of disulﬁde bonds of proteins and in the disposal of
electrophiles and oxidants (29, 51). Thus, the antioxidant
function of GSH is mediated by this redox-active thiol group
that becomes oxidized when GSH reduces target molecules.
The importance of GSH as a cellular redox buffer is under-
scored by the fact that GSH displays a low redox potential
(E’0¼240mV) and is found in high concentration in the cells
(*10–15mM) (52, 72, 95).
Although GSH was initially described as a potent antioxi-
dant, many other cellular functions have been ascribed to
GSH. At present, it is widely accepted that GSH acts not only
as a reducing agent and a major antioxidant within the cells,
but also as a mediator of many other physiologic reactions
including metabolism of xenobiotics, thiol disulﬁde exchange
reactions, and cellular signaling (cell-cycle regulation, prolif-
eration, and apoptosis).
Despite its exclusive synthesis in the cytosol, GSH is dis-
tributed in intracellular organelles, including the endoplasmic
reticulum (ER), nucleus, and mitochondria (Fig. 1). The
compartmentalization of GSH includes separate redox pools
that are distinct from the cytoplasmic pool in terms of the
balance between GSH and GSSG forms, their redox potential,
and their control of cellular activities (95). In the nucleus, GSH
maintains critical protein sulfhydryls that are necessary for
DNA repair and expression (141) and functions also as a hy-
drogen donor in ribonucleotide reductase–catalyzed reduc-
tion of ribonucleotides to deoxyribonucleotides and thus
plays a contributory role in DNA synthesis (60). GSH is found
predominantly in its reduced form, except in the ER, where it
exits mainly as oxidized glutathione (GSSG), GSSG being the
main source of oxidizing equivalents to provide the adequate
environment necessary for favoring disulﬁde bond formation
and the proper folding of nascent proteins (61). In mito-
chondria, however, GSH is foundmainly in reduced form and
represents a minor fraction of the total GSH pool (10–15%).
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Considering the volume of the mitochondrial matrix, the
concentration of mitochondrial GSH (mGSH) is similar to that
of cytosol (10–14mM) (44, 48, 95).
GSSG is accumulated inside the cells, and the ratio of GSH
to GSSG is a good measure of oxidative stress. The GSH=
GSSG redox couple can readily interact with most of the
physiologically relevant redox couples, undergoing revers-
ible oxidation or reduction reactions, thereby maintaining the
appropriate redox balance in the cell (95). Mitochondria are an
excellent example of subcellular organelles whose function
is closely linked to maintenance of redox balance. The mito-
chondria are the primary intracellular site of oxygen con-
sumption and, despite the presence of a wide array of
antioxidants and detoxifying enzymes, are themajor source of
reactive oxygen species (ROS), most of them originating from
the mitochondrial respiratory chain. Conversely, the mito-
chondria are also a target for the damaging effect of oxygen
radicals (38, 65, 109). Although normal electron transport in
mitochondria involves four-electron reduction of molecular
oxygen to water, partial reduction reactions occur even under
physiologic conditions, causing release of O2·
 and hydrogen
peroxide. In accordance with this, it has been estimated that
the steady-state concentration of O2·
 in the mitochondrial
matrix is ﬁve- to tenfold higher than that in the cytosol (15). In
addition, toxic or pathologic conditions that lead to an im-
pairment of mitochondrial function can increase the release of
ROS.
This review summarizes current knowledge of mGSH
control of oxidative stress, mGSH transport, and its role in
cellular apoptosis and in different pathologic settings.
Mitochondrial Control of Oxidative Stress
Although mitochondria are exposed to the constant gen-
eration of oxidant species, the organelle remains functional
because of the existence of an antioxidant defense system to
repair oxidative damage generated during normal aerobic
metabolism. The main redox buffering systems in mitochon-
dria are the glutathione, glutaredoxin, and thioredoxin sys-
tems (Fig. 2).
As mentioned earlier, the mitochondrial respiratory chain
has long been recognized as an effective source of ROS,
predominantly O2·
. Within the mitochondrial matrix, Mn-
dependent superoxidedismutase (MnSOD) convertsO2·
 into
hydrogen peroxide. If the accumulation of hydrogen peroxide
is not limited, it can diffuse to the cytosol or participate in a
chain of reactions that generate more reactive free radicals,
such as hydroxyl radical, which can oxidize mitochondrial
components (proteins, lipids, and DNA). Therefore, mito-
chondria must ensure a balance between the activity of
MnSOD and the GSH redox cycle to dispose of hydrogen
peroxide efﬁciently (38, 95). Because mitochondria lack cata-
lase, the metabolism of hydrogen peroxide is accomplished
mainly by GSH, with the participation of either GSH peroxi-
dase or peroxiredoxin, and by the later conversion of GSSG
back into GSH by the NADPH-dependent GSSG reductase
(GR). Among GSH peroxides (Gpxs) that detoxify hydrogen
peroxide, Gpx1 is the major isoform localized mainly in the
cytosol, with small fraction also present in the mitochondrial
matrix.
mGSH is also the primary defense against oxidative dam-
age tomitochondrial membranes by ensuring the reduction of
hydroperoxide groups on phospholipids and other lipid
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FIG. 1. GSH synthesis and compartmentation. GSH is syn-
thesized in the cytoplasm by the action of g-glutamylcysteine
synthetase (g-GCS) and glutathione synthetase (GS), both en-
zymes requiring ATP. Once synthesized, GSH is distributed in
the endoplasmic reticulum, nucleus, and mitochondria.
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FIG. 2. Mitochondrial control of oxidative
stress. Scheme depicting the different reac-
tions that take place inside the mitochondria
to cope with the oxidative stress derived from
the presence of anion superoxide, hydrogen
peroxide, and hydroxyl radical. GSH peroxi-
dase (Gpx); GSSG-reductase (GR); GSSG,
glutaredoxin (Grx); Mn-dependent superox-
ide dismutase (MnSOD); thioredoxin-2
(Trx2); Trx-reductase (TrxR); peroxiredoxin
III (PrxIII).
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peroxides through the actions of mitochondrial GSH-S-
transferases (GSTs), that exhibit modest Se-independent Gpx
activity, and of Gpx4, a membrane-associated enzyme that is
partly localized to the intermembrane space of the mito-
chondria (19, 109, 129). Actually, because of its capacity to
reduce hydroperoxide groups on phospholipids, cholesteryl
esters, and lipoproteins, Gpx4 is considered a critical de-
fense enzyme in protecting membranes against oxidative
stress. The critical role of Gpx4 is underscored by the fact
that whereas Gpx1-knockout mice are fully viable, Gpx4-
knockout animals demonstrate embryonic lethality, and
Gpx4þ= cell lines are markedly sensitive to inducers of oxi-
dative stress, including g-irradiation, tert-butyl-hydroperoxide,
and hydrogen peroxide, as compared with cell lines derived
from wild-type control littermates (147).
Moreover, GSH can act nonenzymatically by reacting with
electrophiles that are generated as a consequence of metabolic
processes involving both endogenous compounds and xeno-
biotics, although this reaction is greatly enhanced in the
presence of GSTs. Although several cytosolic GSTs isoforms
occur (at least 17 in humans), the only GST present in the
mitochondria is the class kappa isoform (57).
The GSH system collaborates also with the glutaredoxin
system (Fig. 2). Under oxidative-stress conditions, the level of
GSSG increases, which in turn enhances the concentration of
proteinmixed disulﬁdes. A signiﬁcant number of proteins can
be altered in their function by formation of mixed disulﬁdes.
Glutaredoxin (Grx), a GSH-dependent disulﬁde oxidoreduc-
tase, catalyzes dithiol reactions, reducing GSH-protein mixed
disulﬁdes in a coupled system with GR and NADPH as an
electron donor (58, 72). Two knownGrx isoforms are found in
mammals, Grx1 andGrx2. Grx1 is of cytosolic expression, and
Grx2 localizes to both the mitochondrial matrix and nucleus
(90).
Finally, the thioredoxin (Trx) system (Fig. 2), which in-
cludes Trx and Trx-reductase (TrxR), contributes to protein
thiol maintenance. When Trx is in a reduced state, Trx-(SH)2,
the two active-site cysteines form a dithiol group that is able to
catalyze the reduction of disulﬁdes in a number of proteins.
Oxidized thioredoxin (Trx-S2) can be reduced by NADPH
through the catalytic action of the TrxR (113). In addition, the
Trx system can interact also with the peroxiredoxins (Prxs),
which constitute a novel family of thiol-speciﬁc peroxidases
that rely on Trx as the hydrogen donor for the reduction of
hydrogen peroxides and lipid-hydroperoxides (16). One Prx
isoform, PrxIII, is exclusively detected in mitochondria. On
reaction with hydrogen peroxide, the redox-sensitive cysteine
residue of each subunit of PrxIII homodimer is oxidized to
Cys-SOH, which then reacts with neighboring Cys-SH of the
other subunit to form an intermolecular disulﬁde that can be
readily reduced by Trx2 (18, 109).
mGSH Transport
As noted earlier, the concentration of mGSH is in the range
of cytosol GSH. However, unlike cytosol, mitochondria do
not contain the enzymatic machinery to synthesize GSH from
its constituent amino acids (48). GSH can cross easily the
mitochondrial outer membrane (MOM) through porin chan-
nels. However, given the anionic nature of GSH at physio-
logic pH, it cannot diffuse across the mitochondrial inner
membrane (MIM) into the matrix because of the oxidative
phosphorylative–mediated negative membrane potential
relative to the cytoplasm. Oxidized GSSG cannot be exported
into cytosol, so matrix NADPH reduces GSSG to GSH in
the matrix through GR. Consequently, mGSH arises from the
cytosol GSH into the mitochondrial matrix by a carrier-
mediated transport located in the MIM that overcomes the
unfavorable entry against an electrochemical gradient (26, 45,
78, 96) (Fig. 3).
Out of several cloned mitochondrial membrane carriers
(112), the dicarboxylate and the 2-oxoglutarate have been
shown to function as GSH-transporting polypeptides. These
two antiport carriers are electroneutral, because they catalyze
the exchange of anions so that no net transfer of charge occurs
across the MIM (20, 21, 78) (Fig. 3). The reconstitution of re-
combinant mitochondrial dicarboxylate carrier into proteoli-
posomes showed a transport activity for GSH with kinetics,
substrate speciﬁcity, and inhibitor sensitivity similar to those
observed in rat kidney proximal tubules (77). Furthermore,
Lash et al. (77) showed that overexpression of the rat kidney
dicarboxylate carrier in a cell line derived from rat kidney
proximal tubules (NRK-52E) increased themGSHpool size by
two- to 10-fold with respect to wild-type NRK-52E cells, thus
demonstrating a role for this carrier in the mitochondrial
transport of GSH in exchange with inorganic phosphate.
Evidence for a role of the 2-oxoglutarate carrier as a GSH
transporter was based on substrate speciﬁcity and pattern
of inhibition in rabbit kidney mitochondria and in a par-
tially puriﬁed preparation of mitochondrial transporters
from kidney mitoplasts reconstituted in proteoliposomes (20,
21). In addition, the functional expression of the hepatic
2-oxoglutarate carrier in mitochondria from Xenopus laevis,
showing the transport of reduced GSH in a phenylsuccinate-
sensitivemanner (26), further conﬁrmed the suggestion that the
2-oxoglutarate carrier contributes to the transport of GSH in
liver mitochondria. The initial rate of 2-oxoglutarate transport
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FIG. 3. Mitochondrial GSH transport. GSH moves easily
through the mitochondrial outer membrane (MOM); how-
ever, it needs carrier-mediated transport to cross the mito-
chondrial inner membrane (MIM). The dicarboxylate carrier
(DCc) and the 2-oxoglutarate carrier (OGc) have been shown
to function as GSH transporters. In addition, the presence of
unidentiﬁed additional carriers cannot be discarded at
present.
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in rat liver mitochondria was reduced after depletion of
mGSH, suggesting a 2-oxoglutarate=GSH exchange. In con-
trast to the transport of GSH in kidney mitochondria, which
occurs with a single kinetic component (21), the kinetics of
GSH in rat liver mitochondria displays a high-afﬁnity and a
low-afﬁnity component (25, 96). Moreover, the kinetics of
2-oxoglutarate transport in rat liver mitochondria exhibited a
single Michaelis–Menten component with sensitivity to
phenylsuccinate and GSH; in addition, a mutual cis competi-
tionwas found in themitochondrial transport of 2-oxoglutarate
and GSH (26). Intriguingly, the kinetic parameters of the low-
afﬁnity component of GSH transport (25, 96) and that of
2-oxoglutarate (26) are similar, both showing a Michaelis con-
stant in the micromolar range and a similar maximal velocity.
Although this suggests that the 2-oxoglutarate carrier may be
responsible for the low-afﬁnity transport of GSH, alternative
carrier(s) may account for the high-afﬁnity transport of GSH
in rat liver mitochondria (25, 96) (Fig. 3). In line with this, a
recent study showed that incubation of rat liver mitochon-
dria with butylmalonate (a dicarboxylate carrier inhibitor) and
phenylsuccinate (a 2-oxoglutarate carrier inhibitor) inhibited
GSH uptake by 45–50%, suggesting that these two transporters
are only partially responsible for GSH uptake in rat liver mi-
tochondria (153). Moreover, in H4IIE cells, a rat hepatoma
cell line, that were stably transfected with the cDNA for the
2-oxoglutarate carrier, exhibited increased uptake of GSH and
2-oxoglutarate and were protected from cytotoxicity induced
by hydrogen peroxide, methyl vinyl ketone, or cisplatin,
demonstrating the protective function of increased mitochon-
drial GSH transport and mGSH levels in the liver (153).
Because 2-oxoglutarate is a dicarboxylate, it could share the
dicarboxylate carrier for its mitochondrial entry; thus, the
competition seen between 2-oxoglutarate and GSH does not
discard the participation of dicarboxylate carrier in the
transport of GSH in liver mitochondria (26). Although clear
evidence exists of the participation of the dicarboxylic carrier
in kidney (78), its contribution in the transport of GSH in rat
liver seems unlikely for two reasons. First, the transport of
2-oxoglutarate appears to occur preferentially through the
2-oxoglutarate carrier, based on the differential sensitivity to
glutamate inhibition between the 2-oxoglutarate and di-
carboxylate (20, 21, 77). More important, in contrast to the
evidence reported from rabbit kidney, the functional expres-
sion in oocytes microinjected with the dicarboxylate cRNA
from HepG2 cells or rat liver did not result in signiﬁcant GSH
transport activity (26). The reasons for the differential be-
havior of the dicarboxylic carrier in kidney and liver are un-
known and probably reﬂect that interorgan or intercellular
differences may exist regarding mGSH transport.
The function of membrane proteins, including carriers, can
be modulated by the microenvironment of the membrane
where they are inserted. Both the cholesterol=phospholipid
ratio and the saturation state of fatty acyl groups in phos-
pholipids contribute to membrane ﬂuidity changes. Choles-
terol enrichment of cellular or artiﬁcial membranes has been
shown to decrease membrane ﬂuidity.
One of the highlights of mGSH transport through the
2-oxoglutarate carrier in the liver is its dependence on ap-
propriate membrane dynamics. For instance, the initial rate of
2-oxoglutarate transport was reduced in mitochondria from
alcohol-fed rat livers, because of changes in mitochondrial
membrane ﬂuidity induced by alcohol (26). The main deter-
minant for the increase in membrane rigidity in mitochondria
after ethanol intake was a higher cholesterol=phospholipids
molar ratio (25) (Fig. 4). The ﬂuidization of mitochondria
by the ﬂuidizing agent 2-(2-methoxyethoxy)ethyl 8-(cis-2-n-
octylcyclopropyl) (A2C) restored the initial transport rate of
both GSH and 2-oxoglutarate. Additionally, these changes
were reproduced in normal liver mitochondria enriched in
cholesterol where the ﬂuidization of cholesterol-enriched
mitochondria with A2C restored the order membrane pa-
rameter and the mitochondrial 2-oxoglutarate uptake (26). In
line with this observation, cholesterol-enriched mitochondria
from the human hepatocellular cell line HepG2 displayed an
impaired initial rate of GSH uptake at different GSH con-
centrations, an effect that was reversed on ﬂuidization of
mitochondria with A2C, whereas the uptake of ADP through
the adenine nucleotide translocator was unaffected (85).
Secondary to the impaired mGSH transport after pro-
longed ethanol intake in rat liver is the depletion of mGSH
(Fig. 4), underlying the selective depletion of mGSH in the
hepatocytes from alcohol-fed rats (36, 37, 39), which has been
conﬁrmed by other investigations (reviewed in 38). In agree-
ment with the impairment of mitochondrial GSH transport
by alcohol intake, increasing cytosolic GSH levels with
N-acetylcysteine, a GSH precursor, did not increase mGSH in
hepatocytes from alcohol-fed rats (45). However, S-adenosyl-
methionine, which, in addition to promoting GSH synthesis,
was shown to prevent alterations in membrane lipid com-
position including cholesterol=phospholipids increase (103,
117), normalizes mGSH levels in alcohol-fed rats by pre-
venting alcohol-induced membrane-ﬂuidity loss (24, 45).
Thus, alcohol-stimulated cholesterol increase and subsequent
deposition in mitochondrial membrane accounts for the im-
pairment of mitochondrial GSH transport in mitochondria,
leading to depleted mGSH levels.
The key contribution of mGSH in preserving cell viability
was ﬁrst proposed by Meredith and Reed (98, 99) on the basis
of the greatly increased death of hepatocytes when both GSH
pools were experimentally depleted compared with cells with
losses of cytoplasmic GSH alone. Accordingly, in the next
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FIG. 4. 2-Oxoglutarate carrier dependence on membrane
dynamics. A decrease in membrane ﬂuidity in mitochondria,
or an increased cholesterol=phospholipids molar ratio, such
as that observed in rat liver mitochondria after chronic al-
cohol intake, results in impairment of the mitochondrial GSH
transport through the 2-oxoglutarate carrier and, therefore,
in a decrease in mGSH levels.
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sections, we discuss recent data showing the importance of
mGSH in cell regulation and in pathologic states.
mGSH and Apoptosis
Apoptosis, also known as programmed cell death, describes
a particular mode of cell death that is characterized by a series
of biochemical events that lead to a variety of morphologic
changes, includingmembrane blebbing, cell shrinkage, nuclear
fragmentation, chromatin condensation, and chromosomal
DNA fragmentation. Ultimately, apoptotic cells are ingested by
neighboring cells and phagocytes, preventing inﬂammation
and tissue damage that might ensue on cell lysis. Apoptosis is
induced by twomain routes involving either the mitochondria
(the intrinsic pathway) or the activation of death receptors (the
extrinsic pathway) (Fig. 5). Both pathways converge to induce
the activation of caspases, the ﬁnal executioners of cell death.
Caspases are synthesized as proenzymes and require proteo-
lytic processing to be catalytically active. Thus, caspase acti-
vation is the key in the apoptotic process. Caspases with long
prodomains (i.e., caspase-2, - 8, - 9, and - 10) belong to the group
of initiator caspases, and those with short prodomain (i.e.,
caspase-3, - 6, and -7) are the effector caspases. Initiator cas-
pases initiate the apoptotic cascade and lead to the activation of
effector caspases (8, 105, 152).
In the extrinsic pathway, or receptor-mediated pathway,
ligand binding results in the formation of a multiprotein
complex called the death-inducing signaling complex (DISC)
and the activation of procaspase-8 (8, 105). Caspase-8 can
directly activate procaspase-3, an effector caspase mainly re-
sponsible for the cleavage of target proteins essential for
maintaining cellular viability, leading to apoptosis.
However, in certain cell types, in which the direct activa-
tion of caspase 3 by caspase-8 is weak, caspase-8 ﬁrst cleaves
Bid, a Bcl2 family member protein that induces the translo-
cation, oligomerization, and insertion of other Bcl2-family
member such as Bax and=or Bak into the MOM (130), result-
ing in the integration of the extrinsic and intrinsic pathways,
the latter also known as the mitochondrial pathway (Fig. 5).
This is followed by permeabilization of the MOM and release
of several proteins from the mitochondrial intermembrane
space, including cytochrome c. Once cytochrome c is released,
it binds with Apaf-1 and ATP, recruiting procaspase-9 to
create a protein complex known as an apoptosome. The
apoptosome cleaves procaspase-9 to its active form, caspase-
9, which in turn activates the effector caspase-3, resulting in
the execution of apoptosis (79).
Similarly, during the execution of the intrinsic or mito-
chondrial pathway, death signals converge in the mitochon-
dria at the level of translocation of Bax=Bak into the MOM,
triggering the release of cytochrome c to the cytosol, com-
mitment step of the mitochondrial apoptotic cascade (Fig. 5).
Thus, mitochondria are a central organelle in the execution
of apoptosis, in both the extrinsic and the intrinsic pathways,
and hence the regulation of release of cytochrome c from the
mitochondrial intermembrane space is decisive during this
process (59). GSH depletion has been connected to apoptosis
either by predisposing the cells to cell death or by triggering
the modulation of mitochondrial permeabilization and the
activation of effector caspases (4, 27, 54, 106).
As alluded to earlier, because mGSH plays an essential role
in the mitochondrial defense against constant ROS genera-
tion, the depletion of mGSH can pose a critical threat to the
cell by sensitizing mitochondrial components and lipids to
oxidative modiﬁcations by ROS and other reactive species
that could compromise the vital mitochondrial function.
The role of mitochondria in ROS production and apoptosis
and necrosis in mammalian cells is well established and has
been reviewed extensively (10, 67, 95, 109). Accordingly,
protection from oxidative stress by administration of antiox-
idants has been found to increase cell viability in multiple
experimental model systems (32).
FIG. 5. Apoptotic pathways. Apoptosis occurs
through two main pathways: the extrinsic pathway
or death-receptor pathway, and the intrinsic or mi-
tochondrial pathway. Both pathways converge to a
ﬁnal common pathway involving the activation of
caspase-3 that culminates in the execution of cell
death. In many cell types, the extrinsic and intrinsic
pathways are integrated through the cleavage of Bid
by caspase-8, consequently conferring on mitochon-
dria a central role in the control of cell death by
apoptosis.
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Because the concentration of GSH (GSHþGSSG) is so
much higher in comparison to any other system (intracellular
concentration of thioredoxin is 100- to 1,000-fold lower than
glutathione), the GSH=GSSG pool within the cell dominates
the intracellular redox environment and composes the prin-
cipal redox system of the cell (67). Thus, depletion of mGSH
below a certain threshold will endanger detoxiﬁcation pro-
cesses and allow accumulation of hydrogen peroxide and
lipid hydroperoxides.
One of the molecules that can be affected by oxidative
damage ifmGSH levels are compromised is cardiolipin (Fig. 6).
Cardiolipin, an anionic phospholipid found only in mito-
chondria, plays a key role in mitochondrial physiology and
cell-death regulation. Because of its unique structure among
phospholipids, cardiolipin confers ﬂuidity and stability to the
mitochondrial membrane. Cardiolipin is present almost ex-
clusively in the MIM but can be also found at low levels in the
MOM. Cytochrome c is normally bound to the MIM by asso-
ciation with cardiolipin, and it has been postulated that car-
diolipin loss or peroxidation lessens the binding of cytochrome
c to the MIM, favoring the permeabilization of isolated liver
mitochondria and release of cytochrome c (66, 111).
An additional view on the role of cardiolipin in cytochrome
c release comes from studies using synthetic liposomes or
reconstituted membranes, demonstrating that cardiolipin is
required for Bax-mediated pore formation by cooperating
with Bax to form large-scale openings independent of the
formation of large (>100 kDa) Bax aggregates (76).
Moreover, we previously showed that selective depletion
of mGSH after incubation with 3-hydroxy-4-pentenoate (HP)
sensitizes hepatocytes to tumor-necrosis factor-a (TNF-a)
without interfering with NF-kB activation. By using this
strategy, mGSH becomes depleted by 70–80% while sparing
the cytosol pool of GSH (41). Moreover, we observed that
acidic sphingomyelinase (ASMase)–induced ceramide gen-
eration plays a key role in TNF-induced hepatocellular death
and liver injury through stimulation of mitochondrial ROS
(mROS) (41, 94). In further analyzing the role of mGSH on the
sensitization of hepatocytes to TNF, we observed that MOM
permeabilization, cytochrome c release, and procaspase-3
activation take place only after mGSH depletion (93). These
observations suggest that the pre-mitochondrial TNF sig-
naling, including tBid generation and mitochondrial Bax
activation, are independent of the mGSH status, yet their
predicted consequences on mitochondria (MOM permeabili-
zation) and downstream events (cytochrome c release and
apoptosome assembly) are controlled by the levels of mGSH.
This outcome implies that Bax insertion and oligomerization
in MOM, which has been considered a critical determinant of
MOM permeabilization, is not sufﬁcient for TNF-induced
hepatocellular death, requiring additional factors that poten-
tiate or facilitate the ability of Bax to induce MOM permea-
bilization. The most salient observation in this study was that
the formation of oxidized cardiolipin by TNF occurs only in
mGSH-depleted hepatocytes, despite the presence of other
mitochondrial antioxidant defenses such as PrxIII and Trx2,
which are unaffected on mGSH depletion. This oxidized
cardiolipin potentiated the ability of Bax to induce the per-
meabilization in MOM-like liposomes.
Thus, our ﬁndings not only indicate that mGSH levels
control the oxidation state of cardiolipin, but they also de-
scribe a dual role for oxidized cardiolipin in TNF-induced
MOM permeabilization and cell death (Fig. 7): the regulation
of the availability of free cytochrome c and the optimization of
the Bax-lipid pore formation due to structure stress and
membrane remodelling (93). Additionally, these events were
preceded by mitochondrial ROS overgeneration that pre-
dominantly oxidized cardiolipin, changes that were not
observed in acidic ASMase= hepatocytes. Consequently,
ASMase is a critical player in TNF-induced mitochondrial
ROS and subsequent hepatocellular death (41, 94). The ROS
overgeneration observed only after TNF challenge in mGSH-
depleted cells is critical in the regulation of cell death, because
it occurs very quickly (15–30min after TNF), whereas NF-kB–
dependent induction of survival genes take extra time (hours).
In other words, the oxidative changes occurring in mGSH-
depleted hepatocytes precede the upregulation of the NF-kB
survival program, committing hepatocytes to TNF-mediated
cell death.
Thus, strategies to restore mGSH depletion or to prevent
the impairment of its mitochondrial transport may be of
therapeutic signiﬁcance in the treatment of numerous pa-
thologies, as discussed in the following section.
mGSH in Pathologic Settings
Hypoxia and reperfusion injury
Hypoxia occurs in tissues when the availability of O2 is
insufﬁcient for the cellular demand, as happens in physiologic
(embryonic development, exercising muscle) and pathologic
conditions (stroke, tissue ischemia, inﬂammation, solid-tumor
formation) (6, 116, 126, 132, 143). Molecular oxygen is re-
mGSH mGSH
CL CLOOH
ROS
ROS
Apoptotic signal Apoptotic signal
cyt c
cyt c
Cell death
mGSH depletion
mGSH controls cardiolipin oxidation 
Normal mGSH level
FIG. 6. mGSH control of cardiolipin oxidation.
Under normal conditions, mGSH is able to cope with
the stress derived from many apoptotic stimuli.
However, depletion of mGSH below a certain
threshold will compromise ROS detoxiﬁcation, lead-
ing to its accumulation, resulting ultimately in car-
diolipin oxidation.
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quired for the maintenance of aerobic metabolism, being an
essential electron acceptor in many cellular reactions, espe-
cially in the mitochondrial respiratory chain. Although hyp-
oxia was previously shown to stimulate a burst of ROS of
mitochondrial and extramitochondrial origin (e.g., xanthine
oxidase), recent evidence demonstrated the critical role of
ROS production from the mitochondrial electron-transport
chain (65), in particular through superoxide release to the
intermembrane space by complex III (13, 49). Under normal
redox status, cells adapt and survive because of the existence
of speciﬁc sensors and the activation of a number of genes
stimulated by O2 deprivation. However, when the hypoxic
insult is strong and sustained, or the mitochondrial antioxi-
dant defense is compromised, or both, cell viability may be at
risk. In this sense, mGSH depletion was shown to sensitize
primary hepatocytes to O2-induced ROS generation, an effect
prevented by rotenone plus TTFA, which abolishes mito-
chondrial ROS generation, or on GSH replenishment by GSH
ester (86). These results suggest that mGSH restoration may
be an effective strategy in protecting perivenous hepatocytes
from chronic alcohol intake because of mGSH depletion and
exposure to hypoxia and TNF (24, 86).
Among the genes stimulated by O2 deprivation, one of
the best characterized is the hypoxia-inducible factor (HIF),
a heterodimeric transcription factor [consisting of an O2-
regulated a subunit (HIFa) and a constitutively expressed
b subunit (HIFb)] that upregulates genes involved in angio-
genesis, proliferation, and glycolysis (6, 116, 126, 132, 143). In
normoxic cells, the hydroxylation of proline residues in the
oxygen domain within HIF by HIF prolyl hydroxylases
(PHDs) enables the binding to the von Hippel–Lindau tumor-
suppressor protein (VHL), leading to the ubiquitinization and
subsequent proteasome-dependent degradation of HIF-1a
subunits (68, 70). However, when O2 decreases, PHDs be-
come inhibited, and HIF-a subunits are subsequently stabi-
lized. Recent studies provided clear-cut evidence for a role of
mitochondrial reactive oxygen species (mROS) in HIF-1a ac-
tivation by using genetic and biochemical approaches (13, 49,
65, 86). Blocking superoxide anion production by suppres-
sing the Rieske iron-sulfur protein of complex III impairs
HIF-1a induction by hypoxia, and moreover, hydrogen
peroxide or agents that produce mROS activate HIF-1a
during normoxia (65), indicating a central role for ROS in
HIF-1a stabilization.
Dual role of cardiolipin oxidation in promoting MMP
a Cardiolipin Oxidation enhances Cyt c availability
b Cardiolipin Oxidation maximizes Bax-mediated pore formation
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FIG. 7. Dual role of cardiolipin oxidation in promoting mitochondrial membrane permeabilization (MMP). Oxidized
cardiolipin exerts a dual role in TNF-induced MOM permeabilization and cell death: (a) contributes to the availability of free
cytochrome c; and (b) maximizes the Bax-lipid pore formation, without affecting Bax translocation and oligomerization to the
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HIF-1a stabilization and NF-kB activation may also have a
role in promoting the survival of cancer cells, angiogenesis,
neovascularization, glycolytic ATP generation, and tumor
invasion. Therefore, hypoxia-induced mROS may promote
cancer development and progression. However, over-
generation of mROS, occurring after mGSH depletion or by
blocking mitochondrial respiration (84, 114), may sensitize
tumor cells by inhibiting the NF-kB survival pathway (Fig. 8).
Because hypoxia is expected to affect predominantly cells
from solid tumors, more than cells from healthy tissues, the
combination of mGSH depletion, or strategies that increase
mROS, and hypoxia may be an interesting approach in cancer
therapy that deserves further study.
In addition, hypoxia-induced mROS have been shown
to enhance the DNA binding of NF-kB through a redox-
dependent mechanism (17). The canonic pathway of NF-kB
activation by a wide variety of stimuli involves the phos-
phorylation of the inhibitory subunit IkB at speciﬁc serine
residues that targets it subsequent degradation by the pro-
teasome (5, 140), allowing NF-kB transactivating subunits to
translocate to the nucleus and to bind speciﬁc sites in the
promoter=enhancer region of target genes. However, an ad-
ditional pathway of NF-kB activation without IkB-a proteo-
lytic degradation (62) is triggered by hypoxia (73) because of
the phosphorylation of IkB-a at tyrosine residues. Interest-
ingly, this alternative NF-kB–activation pathway has been
characterized in hypoxic cells by a c-Src–mediated mech-
anism (31, 84) that was prevented in mutants expressing
a redox-insensitive c-Src (84). Similarly, tyrosine phosphory-
lation of IkB-a due to c-Src activation by mROS has been ob-
served in hypoxia-related clinical settings, such as ischemia=
reperfusion (I=R) liver injury (83, 154), in which NF-kB tran-
scription of protective proteins in parenchymal cells emerges
as a key mechanism regulating the ﬁnal outcome (83).
Therefore, ROS generation after (I=R) is responsible for the
induction of Src-phosphorylation, NF-kB activation, and
transcription of kB-dependent protective genes, such as
MnSOD, in hepatocytes. However, extended ischemia in-
duces a massive production of ROS and GSSG genera-
tion, which antagonizes NF-kB gene induction, similarly to
that previously observed in hepatocytes after TNF exposure
(87), consistent with the notion that NF-kB activation requires
a balanced level of GSSG (30). The predominant bulk of ROS
are generated during the reperfusion phase after ischemia,
associated with increasing levels of TNF in serum and liver.
Given that TNF is an important inducer of mROS, the role of
mGSH may be key in I=R injury. TNF was shown to play a
central role in I=R damage (124). However, the molecular
signaling of TNF in I=R is not well established. In addition to
the protein–protein interactions underlying the signaling of
TNF on its binding to its receptor TNFR1, TNF also is known
to give rise to sphingolipid intermediates, such as ceramide
and ganglioside GD3, which have been shown to interact
with mitochondria and generate ROS (42, 43). In line with
this, prevention of ceramide production may be an effec-
tive strategy to protect the liver against I=R-induced injury
(82). Thus, ROS generation may play a dual role in I=R in-
jury. Although preventing ROS overgeneration by antioxi-
dants may be of therapeutic value, the early counteraction
of ROS generation during ischemic preconditioning was
shown to cancel the protective mechanisms triggered by pre-
conditioning, including MnSOD overexpression (120, 125).
Conversely, ischemia-mediated NF-kB–dependent induc-
tion of inﬂammatory proteins by Kupffer cells, resident
macrophages in the liver, occurs mainly through a redox-
independent canonic pathway of NF-kB activation during I=R
(83) triggered by ligands such as TNF or LPS, consistent with
the protection observed in knockout models that block this
receptor-mediated signaling (89, 137) or after Kupffer cell
inactivation (63, 82). Therefore, mitochondrial redox status
and particularly mGSH may determine liver function after
prolonged ischemia, and reduction of mitochondrial oxida-
tive stress would be a valid therapeutic strategy to improve
the outcome of livers exposed to I=R.
Liver diseases
The liver is one of the organs with the highest content of
GSH, and alterations in its regulation can contribute to several
pathologies. In particular, hepatic mitochondria are recog-
nized as a major source of ROS, which in turn can regulate
vital liver functions and disease pathogenesis (95).
Studies in animal models of prolonged ethanol feeding
showed functional alterations in the oxidative phosphory-
mGSH depletionNormal mGSH levels
ROS ROS
mGSH mGSH
HYPOXIA HYPOXIA
HIF-1α
NF-κB
HIF-1α
NF-κB
Cell Survival Cell Death
mGSH depletion sensitizes tumor cells to hypoxia
FIG. 8. mGSH depletion sensitizes tumor
cells to hypoxia. HIF-1a stabilization and NF-kB
activation participate in promoting survival of
cancer cells under hypoxic conditions. However,
overgeneration of mitochondrial ROS, as ob-
tained after mGSH depletion, may sensitize tu-
mor cells by inhibiting the NF-kB survival
pathway, despite HIF stabilization.
2692 MARI´ ET AL.
lation, whereas patients with alcoholic steatohepatitis
(ASH) displayed mitochondria with morphologic and func-
tional aberrations (12, 123, 138). As mentioned earlier, one of
the clues to the progression of ASH relates to the alcohol-
mediated susceptibility of hepatocytes to cell death by reac-
tive oxygen species (ROS) and inﬂammatory cytokines (38).
TNF has been considered a key ASHmediator, with ASMase-
mediated ceramide generation playing a critical role (41, 93).
Furthermore, alcohol feeding has been shown to sensitize he-
patocytes to TNF because of the limitation of mGSH through
impaired transport of GSH to the mitochondria, as a result of
the altered membrane-order parameter caused by mitochon-
drial cholesterol increase (26, 38, 85). Selective pharmacologic
depletion of mGSH sensitizes hepatocytes to TNF-mediated
cell death, which reproduces the observations found with
alcohol feeding (24, 34). This selective mGSH depletion after
alcohol intoxication was conﬁrmed by others (144, 150, 151).
ASH andnonalcoholic steatohepatitis (NASH) are two of the
most common forms of liver disease worldwide and represent
an advanced stage in the spectrum of fatty liver diseases. Al-
though the primary etiology of ASH and NASH is different,
these two diseases show almost identical histology, character-
ized by steatosis (macrovesicular more than microvesicular),
mixed lobular inﬂammation with scattered polymorphonu-
clear leukocytes as well as mononuclear cells, and hepatocel-
lular cell death and ballooning due to sensitivity to oxidative
stress and ﬁbrosis. Besides the accumulation of lipids in the
cytoplasm of hepatocytes, mostly in the form of free fatty acids
(FFA) and triglycerides (TG), cytokine overexpression, partic-
ularly TNF and the membrane receptors, was shown to con-
tribute to steatohepatitis and subsequent progression to
hepatocellular apoptosis in both ASH and NASH (33, 148).
Thus, the understanding of the mechanisms that determine the
susceptibility of steatotic hepatocytes to inﬂammatory cyto-
kines (e.g., TNF=Fas) is of relevance to develop novel thera-
peutic strategies for the treatment ASH and NASH. In a recent
study, by using genetic and nutritional models of NASH, we
observed that free cholesterol accumulation in mitochondria,
but not TG or FFA loading, sensitizes hepatocytes to TNF,
contributing to the transition from steatosis to steatohepatitis
through mGSH depletion (92). In addition, the treatment of
obese mice with atorvastatin prevented the free-cholesterol
accumulation in mitochondria and the subsequent mGSH de-
pletion, thus abolishing the susceptibility to cytokine-induced
liver damage (92). Thus, because free-cholesterol deposition
inﬂuences the mitochondrial transport of GSH by modulation
ofmembrane physical properties, the transport of cholesterol to
mitochondria may be of signiﬁcance in pathologic states, such
as in ASH and NASH, and merits further study (34).
In line with this, liver cirrhosis also is characterized by
mitochondrial dysfunction, and similar ﬁndings on mGSH
regulation have been reported (74, 75). For instance, second-
ary biliary cirrhosis in rats induced by bile-duct ligation
caused the depletion of mGSHwith respect to sham-operated
controls; interestingly, this depletion preceded the decrease of
GSH levels in liver homogenates (75). Although the mecha-
nism involved was not further investigated, mitochondria
from bile duct–ligated rats exhibited altered lipid composi-
tion with a two- to threefold increase in the cholesterol=
phospholipid ratio in the mitochondrial inner membrane (74),
thus suggesting the possibility of impaired transport of GSH
into mitochondria.
Another clinical setting inwhichmGSH levels are of critical
importance is in drug toxicity (97, 98). Acetaminophen, or
N-acetyl-p-aminophenol, is a widely used analgesic consid-
ered to be safe when taken at therapeutic doses; however, it
causes a potentially fatal, hepatic centrilobular necrosis when
taken in overdose. Acetaminophen is metabolically activated
by cytochrome P450 enzymes to a very reactive metabolite,
N-acetyl-p-benzoquinone imine (NAPQI), which is detoxiﬁed
by conjugation with GSH. Thus, acetaminophen overdose
causes a severe depletion of GSH levels. The current clinical
treatment, or antidote, for acetaminophen overdose is
N-acetylcysteine, a GSH precursor that can replenish cellular
GSH levels (101, 107). NAPQI initiates its toxicity by ﬁrst at-
tacking mitochondria (14, 107, 139), followed by mGSH de-
pletion (142). Although acetaminophen can decrease GSH in
both cytosol and mitochondria, the kinetics of GSH depletion
in hepatocytes exposed to acetaminophen showed that the
depletion of mGSH preceded that of cytosol GSH (142), in-
dicating the relevance of this pool of GSH in the hepato-
toxicity of acetaminophen. In addition, and similar to what
happens with many other drugs, acetaminophen cytotoxic-
ity is mediated through mitochondrial membrane permeabi-
lization (47), and agents that block it, such as cyclosporin
A, protect hepatocytes against acetaminophen-induced cell
death (53). Hence, these observations highlight the impor-
tance of mGSH in drug toxicity.
Neurologic disorders
Despite the evidence for the important role of mGSH in
nonneural cells, surprisingly little attention has been given to
the properties and functions of this antioxidant pool in cells
from the central nervous system (134). Cerebellar granule
neurons in culture exhibit marked functional deterioration
and die in response to complete loss of both the mitochon-
drial and cytoplasmic GSH, but not with cytoplasmic GSH
loss alone (146). Additionally, although astrocytes with
mGSH depletion did not show changes in viability compared
with nondepleted mGSH astrocytes, they were much more
susceptible to nitric oxide exposure (104).
It was reported that an early and selective loss of mGSH in
mitochondria isolated from rat brain in a model of stroke by
occlusion of the middle cerebral artery (2, 133) resulted in
enhanced brain injury and repletion of mGSHwith GSH-ester
resulted in reduced infarct volume by>60% (1).
The brain is particularly vulnerable to oxidative damage
because of its high oxygen use, content of oxidizable poly-
unsaturated fatty acids, and presence of redox-active metals
(Cu, Fe). Oxidative stress increases with age, and therefore,
it can be considered an important causative factor in sev-
eral neurodegenerative disorders, such as Alzheimer disease
(AD) (141). The brains of Alzheimer disease patients show a
signiﬁcant extent of oxidative damage associated with
marked accumulation of amyloid-b peptide (Ab), the main
constituent of senile plaques in the brain (50, 136). Current
evidence indicates that targeting of Ab to intracellular sites,
most notably mitochondria, causes oxidative stress, mito-
chondrial dysfunction, and cell death (80, 91). Ab may cause
mitochondrial ROS production, but also it is becoming clear
that oxidative damage occurs early in the AD brain, even
before the onset of signiﬁcant plaque pathology (81). ROS
may activate signaling pathways that alter the amyloid
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precursor protein or tau processing (88), and oxidant-induced
inactivation of critical molecules, such as Pin1, may also play a
contributing role (135). Together, these results suggest that
oxidative damage and subsequent mitochondrial dysfunction
probably contribute causally to AD-related pathology.
In addition, epidemiologic observations identiﬁed hyper-
cholesterolemia in midlife as a major risk factor for AD (3,
145). The epidemiologic evidence linking cholesterol to AD
was further supported by in vitro studies (69, 110), showing
that membrane cholesterol promotes the amyloidogenic pro-
cessing of the amyloid precursor protein (APP) to generate
Ab. In a recent study in our laboratory with genetic mouse
models of brain cholesterol accumulation, such as Tg-SREBP-
2 (35), we expanded the role of cholesterol and mGSH in AD,
indicating that, in addition to fostering Ab-production, mi-
tochondrial cholesterol loading modulates Ab neurotoxicity
through selective mGSH depletion. Although total GSH de-
pletion and altered GSH redox cycle have been described in
AD (9, 121), two lines of evidence indicate that the mGSH
depletion speciﬁcally accounted for the increased suscepti-
bility to Ab. First, the fact that the pool of mGSH rather than
cytosol GSH determines the sensitivity of brain mitochondria
to Ab-mediated oxidative stress and release of intermembrane
apoptotic proteins is dependent on the levels of mGSH.
Second, treatment with GSH ethyl ester, which recovers the
depleted pool of mGSH, prevents the enhanced neuroin-
ﬂammation and neuronal damage observed in Tg-SREBP-2
mice after Ab intracerebroventricular infusion (35). Collec-
tively, these results imply that efforts should be directed
speciﬁcally to replenish mGSH to slow disease progression,
by using, for instance, strategies that bypass the block of GSH
transport into mitochondria imposed by cholesterol deposi-
tion.
Because many neurologic disorders are characterized by
oxidative stress and mitochondrial dysfunction, the possible
participation of mGSH in clinical settings other than AD
cannot be discarded. For instance, Parkinson’s disease (PD) is
characterized by a mitochondrial dysfunction, and estab-
lished animal models of PD are based on prolonged infusion
of inhibitors of complex I of the mitochondrial electron-
transport chain, such as rotenone (131) or MPTP (40). These
animals have a parkinsonian phenotype distinguished by
progressive rigidity, bradykinesia, and tremor, and patho-
logically by nigral degeneration with presence of Lewy bod-
ies, cytoplasmic inclusions immunoreactive for a-synuclein
and ubiquitin. Interestingly, one of the earliest biochemical
derangements observed in patients with PD is loss of total
GSH levels (115), which may contribute to progressive cell
death. In addition, a reduction in both cellular and mito-
chondrial GSH levels results in increased oxidative stress
and a decrease in mitochondrial function through a selective
decrease in complex I activity, probably through an NO-
mediated mechanism (22). Brain GSH elevation by means of
GSH-ethyl ester protected against dopamine loss in a long-
termmodel of mitochondrial impairment used tomimic PD in
rat (149). Related to the mitochondrial injury observed in PD
patients, total GSH depletion has been shown to precede the
decreases in both mitochondrial complex I activity and do-
pamine levels (7), suggesting a role of mGSH in this pathol-
ogy. Therefore, strategies aimed to boost mGSH levels in
brain may result in clinical beneﬁt or neuroprotection or both
in animal models or in human diseases.
Diabetes
The mGSH pool also seems to be an important player in
diabetes. The majority of diabetes patients have type-2 dia-
betes (90%), or non–insulin-dependent diabetes. Thus, de-
creased uptake of glucose into muscles and adipose tissue
leads to chronic hyperglycemia that can result in tissue
damage. The rate of the ROS production depends on the
metabolic status of the cell; for instance, during hyperglyce-
mia, the increased substrate availability for mitochondrial
oxidation generates a high mitochondrial inner-membrane
potential, leading to inhibition of further electron transfer,
predominantly at complex III, increasing the risk for reduc-
tion of molecular oxygen into the superoxide (11). Hy-
perglycemia has been shown to increase the enzymatic
conversion of glucose to sorbitol by sorbitol dehydrogenase,
with concomitant decreases in NADPH and GSH. This de-
pletion in reducing equivalents results in augmented sensi-
tivity to oxidative stress (122). A good example of the effect of
hyperglycemia onmitochondrial stress is diabetic retinopathy
(71), in which retinal mitochondria display a twofold increase
in superoxide levels in diabetic mice compared with nondia-
betic mice. In the same retina, hyperglycemia decreased
mGSH levels by 40%, and it increased mitochondrial mem-
brane permeability (swelling) by more than twofold. Simi-
larly, oxidative stress due to excessive ROS and depleted
mGSH can give rise to cardiomyocyte apoptotic cell death in
diabetic hearts, leading to heart disease (46, 127), under-
scoring the importance of mGSH loss in diabetes-mediated
cardiac apoptotic death.
Aging
The biologic basis of aging is unknown, and numerous
theories reﬂect some of the current directions in biologic aging
research. Among these, the ‘‘shortening of the telomeres’’ and
the ‘‘free radical’’ theories have attracted special attention re-
cently.
The free radical or oxidative stress theory of aging, ﬁrst
proposed by Harman (55) in 1956, states that the age-related
loss of physiological function is due to the progressive ac-
cumulation of oxidative damage, which ultimately deter-
mines the life span of an organism. Shortly after the discovery
of themitochondrial genome (mtDNA), Harmanmodiﬁed his
original theory to incorporate the contribution=role of mito-
chondria in oxidative stress and proposed the mitochondrial
theory of aging (56). In subsequent years, the mitochondrial
theory of aging was further reﬁned and developed by Miquel
and colleagues (100), who suggested that the accumulation of
somatic mutations in the mtDNA induced by oxidative stress
is themajor contributor of aging and age-related degenerative
diseases. Currently, the mitochondrial theory of aging implies
the overgeneration of ROS derived from the mitochondrial
respiratory chain, which damage macromolecules, especially
mtDNA. As a result, an accumulation of mtDNA mutations
leads to production of defective mitochondrial respiration,
further increasing ROS generation and oxidative damage.
This so-called ‘‘vicious cycle’’ of ROS generation and con-
comitant oxidative damage is proposed as the ultimate de-
terminant of mammalian life span (64). Accordingly, studies
in mice have indicated that during aging, the glutathione
redox state (GSH=GSSG ratio) in tissues and mitochondria
shifts progressively toward oxidation (28, 118, 119), and a
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signiﬁcant decrease in mGSH levels in brain, skeletal mus-
cle, and liver of senescence-accelerated mice (displaying
48% shorter average life span than control mice) was re-
ported (119). In addition, another study pointed to a striking
relation betweenmtDNAdamage and glutathione redox state
in mitochondria (28). It is known that mtDNA is more sus-
ceptible to oxidative damage because of the lack of protective
histone-like proteins in the mitochondria, its open circular
structure, and their limited repair capacity. In accordance,
mtDNA displays an increased susceptibility to the radiation-
induced loss of integrity compared with nuclear DNA, an
effect that was potentiated by GSH depletion in mitochon-
dria (102).
Given that the aging process is associated with a gradual
prooxidizing shift in the glutathione redox state, more stud-
ies aimed to address the speciﬁc role of mGSH and GSH-
replenishing agents are needed in this area.
Other pathologies
Lungs are among the major sources of GSH storage
(6.1–17.5nmol=mg lung) and have higher levels of
g-glutamylcysteine synthetase than other tissues. Alterations in
the levels of reduced GSH in the lung-lining ﬂuid have been
shown in various inﬂammatory conditions. GSH deﬁciency
has been largely correlatedwith pulmonary diseases, including
chronic pulmonary disease, acute respiratory distress syn-
drome, neonatal lung damage, and asthma (23). A clinical
setting in which mGSH levels are of utmost importance is hy-
peroxia or administration of supplemental oxygen; despite
being an important clinical therapy, it can cause signiﬁcant
lung damage. In line with this, prematurely born human in-
fants, which exhibit underdeveloped lungs, frequently
require supportive therapies that use elevated oxygen con-
centrations that put them at risk for developing pulmonary
oxygen toxicity. This risk is made even greater by the im-
maturity of the cellular antioxidant defenses. Although the
exact mechanisms of oxygen toxicity are still not fully de-
ﬁned, cellular damage is probably mediated by increased
production of chemically ROS in the mitochondria. Thus, in
conditions that increase mitochondrial production of ROS,
such as exposure to high concentrations of oxygen, therapies
based on enhancing mGSH concentrations could be highly
beneﬁcial (108).
Moreover, in models of chemical toxicity, nephrotoxicity
and renal cell apoptosis induced by cisplatin have been as-
sociated with mitochondrial dysfunction and decreases in
mGSH and NADPH levels, as well as in loss of mitochondrial
membrane potential and cardiolipin oxidation, leading to cell
death by apoptosis, as evidenced by the increased caspase-3
activity (128).
Concluding Remarks
Through the control of the mitochondrial oxidative stress,
mGSH is as a critical factor in the control of cell survival=
death. The signiﬁcance of mGSH in this regard has been il-
lustrated by the increasing number of pathologic settings in
which its depletion results in increased cellular damage and
hence cell death. Thus, modulation of mGSH levels can in-
ﬂuence disease progression, and therapies to enhance mGSH
levels could be of medical signiﬁcance in the treatment of
numerous human diseases. However, although our knowl-
edge of its regulation at the level of transport across the mi-
tochondrial inner membrane has increased substantially in
recent years, further characterization of its transport system is
needed to ensure cell-type–speciﬁc modulation of mGSH
levels to regulate disease pathogenesis. Whereas the use of
cell-permeable GSH prodrugs may be a critical strategy to
regulate diseases characterized by mGSH depletion, such as
steatohepatitis and cholestasis, in liver malignancies, a pre-
ferred alternative will be preferentially to deplete mGSH to
sensitize liver cancer cells against hypoxia.
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Abbreviations Used
Ab¼ amyloid-b peptide
ASH¼ alcoholic steatohepatitis
ASMase¼ acidic sphingomyelinase
GPx¼GSH peroxidase
GR¼GSSG-reductase
Grx¼ glutaredoxin
GSH¼ glutathione
GSSG¼ oxidized GSH
GST¼GSH-S-transferase
HP¼ 3-hydroxy-4-pentenoate
mGSH¼mitochondrial GSH
MIM¼mitochondrial inner membrane
MnSOD¼Mn-dependent superoxide dismutase
MOM¼mitochondrial outer membrane
mtDNA¼mitochondrial genome
NASH¼nonalcoholic steatohepatitis
ROS¼ reactive oxygen species
TNF-a¼ tumor necrosis factor alpha
Trx¼ thioredoxin
TrxR¼Trx-reductase
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